$TONX

Telegram starts rolling out Gram Wallet, designed to support potentially hundreds of millions

TON Strategy (TONX) approved two TON network upgrades: Config -123 for Telegram's Gram Wallet and Config 30 for network throughput. Gram Wallet, now rolling out, uses a validator-governed smart contract architecture, supporting features like key rotation and potential future upgrades. Config 30 aims to increase network throughput by up to 30%. TONX shares fell 3.24% post-announcement.

Original reporting
Published Sep 1, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 3:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefTechnology
Primary signal
$TONX
Bearish
medium confidence
Mentioned
$TONX
Relevance
6/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$TONXBearishMed
01

Why it matters

The network upgrades aim to improve scalability and enable seamless wallet updates, but the immediate stock reaction was negative.

02

Market read

The announcement introduces new infrastructure for a major messaging platform's crypto wallet, affecting TONX and the broader crypto infrastructure sector.

03

What to watch

Potential regulatory scrutiny of Telegram's crypto activities could dampen long‑term upside.

Relevance 6/10Novelty 7/10Timing: today

Background

Telegram is rolling out its native Gram Wallet, backed by TON network upgrades voted on by TON Strategy.

Company-level read

Ticker impact

$TONXBearishMedium confidence
Context

TON Strategy (NASDAQ:TONX) voted for two TON network upgrades enabling Telegram's Gram Wallet, causing a 3.24% share decline.

Expected impact

Potential rebound if wallet adoption accelerates; short‑term downside risk remains.

Evidence & confidence

Upgrade announcements are new but the micro‑cap's stock moved down on the news, indicating traders view the impact as uncertain.

Market effects

Highlights growing infrastructure support for blockchain wallets, relevant for crypto‑related service providers.

Primarily affects US‑listed micro‑cap and broader crypto ecosystem; limited broader market effect.

Shows Telegram's move into native crypto, a signal for global digital asset adoption trends.

Counterpoint

The upgrades may not translate into user adoption quickly, keeping pressure on TONX shares.

Key entities

  • TON Strategy Company

    Digital asset treasury firm (NASDAQ:TONX) supporting The Open Network.

  • Telegram

    Messaging app launching the Gram Wallet.

Related articles

$TONXMedAI 8/10

TON Strategy (TONX) Q2 2026 Earnings Call Transcript

TON Strategy Company (TONX) reported Q2 2026 results on an earnings call. Revenue was $15 million, driven by higher staking rewards from its Gram holdings. Fair value of digital assets rose to $369.5 million. Net income from continuing operations was $83.5 million, with operating income of $0.5 million. Management cited TON upgrades improving speed and costs and expects $4 million to $5 million in annual OpEx savings.

$TONXMed

TON Strategy Co (TONX): Results of Operations and Financial Condition

TON Strategy Co (TONX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TON Strategy Company Reports Second Quarter 2026 Financial Results Generated $15.0 million of Gram staking revenue Held approximately 230.5 million Gram at June 30, including approximately 229.9 million Gram deployed in staking Executed primary actions expected to re

$TONXMed

TON Strategy Company Advances Share Repurchase Program

TON Strategy Company (Nasdaq: TONX) said it entered a Rule 10b5-1 plan to repurchase its common stock over a two-month period starting July 1, 2026. The plan follows an existing $250 million authorization announced Sept. 3, 2025, with Virtu Financial as executing broker. The company also focuses on accumulating Gram for its treasury strategy.

$CYTKMedAI 8/10

Could Aficamten Give Cytokinetics the First Approved nHCM Treatment?

Cytokinetics (NASDAQ:CYTK) reported late-stage trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), meeting primary goals of improving symptoms and quality of life. The study showed 53% of patients on aficamten improved in key areas vs. 13% on placebo, but lacked significant structural or cardiovascular benefits. The company plans a US marketing application in Q4 2026. Analysts forecast peak sales of over $5 billion for Myqorzo, but investors expressed concerns over

$CCJMed

Jefferies Sees Cameco (CCJ) and BWXT as Winners in the Nuclear Boom

Jefferies initiated coverage of Cameco (CCJ) and BWXT (BWXT) with 'Buy' ratings, setting price targets of $138 and $181 respectively, citing strong long-term prospects in nuclear energy. CCJ, a major uranium producer, and BWXT, a nuclear reactor provider, are positioned to benefit from global and U.S. initiatives to expand nuclear capacity. Both companies face risks, including uranium price volatility for CCJ and execution challenges for BWXT.